Genetic Signatures Ltd. (AU:GSS)
ASX:GSS
Want to see AU:GSS full AI Analyst Report?
GSS Stock Chart & Stats
AU$0.24
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.24
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.44
Previous CloseN/A
Volume34.30K
Average Volume (3M)149.45K
Market Cap
AU$17.72M
Enterprise Value-AU$864.42K
Total Cash (Recent Filing)AU$29.87M
Total Debt (Recent Filing)AU$653.00K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding227,138,820
10 Day Avg. Volume161,537
30 Day Avg. Volume149,454
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)1.65
Price to Sales (P/S)5.20
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.10Price Target Upside-58.33% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.08
Revenue Forecast (FY)AU$18.20M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueGSS’s core business sells consumable PCR test kits, creating recurring revenue as installed labs reorder kits per test volume. This installed-base, usage-driven model gives durable revenue visibility and customer stickiness as long as labs keep running tests and adopting assay panels.
Proprietary 3base TechnologyOwnership of a proprietary 3base multiplex PCR platform is a durable competitive asset: it enables multi-pathogen panels and high-throughput workflows that reduce per-test costs and lab complexity. This differentiation supports adoption by clinical/reference labs and raises barriers to direct competition.
Low Leverage And Strong Equity PositionA very low debt burden and strong equity base reduce refinancing risk and give management more strategic flexibility to fund R&D, commercial expansion or handle temporary cash shortfalls without immediate pressure from creditors, supporting longer-term operational continuity.
Bears Say
Persistent UnprofitabilitySustained negative net, EBIT and EBITDA margins indicate the company is not yet generating operating profits. This undermines internal funding for growth and R&D, pressures returns on equity, and means long-term viability depends on achieving structural margin improvement or continual external funding.
Negative Operating And Free Cash FlowsOngoing negative operating and free cash flow imply cash burn from operations. This creates a persistent financing need that can force dilutive capital raises, constrain investment in commercial scale-up and manufacturing, and increase execution risk for product commercialization plans.
Modest Revenue Growth Not Yet Translating To ProfitsRevenue growth in the high-single-digits shows market traction but has not converted to positive margins. This suggests scalability or pricing/unit-cost issues: unless revenue growth accelerates or unit economics improve, the top-line gains will be insufficient to offset fixed costs and R&D spend.
Genetic Signatures Ltd. News
GSS FAQ
What was Genetic Signatures Ltd.’s price range in the past 12 months?
Genetic Signatures Ltd. lowest share price was AU$0.07 and its highest was AU$0.43 in the past 12 months.
What is Genetic Signatures Ltd.’s market cap?
Genetic Signatures Ltd.’s market cap is AU$17.72M.
When is Genetic Signatures Ltd.’s upcoming earnings report date?
Genetic Signatures Ltd.’s upcoming earnings report date is Aug 24, 2026 which is in 76 days.
How were Genetic Signatures Ltd.’s earnings last quarter?
Genetic Signatures Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.028 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.028.
Is Genetic Signatures Ltd. overvalued?
According to Wall Street analysts Genetic Signatures Ltd.’s price is currently Overvalued.
Does Genetic Signatures Ltd. pay dividends?
Genetic Signatures Ltd. does not currently pay dividends.
What is Genetic Signatures Ltd.’s EPS estimate?
Genetic Signatures Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genetic Signatures Ltd. have?
Genetic Signatures Ltd. has 227,138,820 shares outstanding.
What happened to Genetic Signatures Ltd.’s price movement after its last earnings report?
Genetic Signatures Ltd. reported an EPS of -AU$0.028 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -13.043%.
Which hedge fund is a major shareholder of Genetic Signatures Ltd.?
Currently, no hedge funds are holding shares in AU:GSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genetic Signatures Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
AU$0.10 (-58.33% Downside)
AU$0.10 (-58.33% Downside)
Blogger Sentiment
Bullish
AU:GSS Sentiment 75%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.35%
12-Months-Change
Fundamentals
Return on Equity
-23.93%
Trailing 12-Months
Asset Growth
-16.90%
Trailing 12-Months
Company Description
Genetic Signatures Ltd.
Genetic Signatures Limited operates as a molecular diagnostics (MDx) enterprise, extending its reach across Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. The company engineers and manufactures an array of real-time Polymerase Chain Reaction (PCR)-based products, sold under the EasyScreen brand, for the identification of infectious diseases. Moreover, it offers its proprietary MDx 3Base platform technology, enabling hospitals and pathology laboratories to conduct comprehensive screenings for diverse infectious pathogens. Its offerings also encompass detection kits tailored for conditions such as gastrointestinal ailments, respiratory illnesses, sexual health concerns, antimicrobial resistance, meningitis, and tropical diseases. Founded in 2001, the firm is headquartered in Newtown, Australia.
GSS Stock 12 Month Forecast
Average Price Target
AU$0.10
▼(-58.33% Downside)
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Cryosite Limited
―
Inoviq Ltd
―